[Analysis of the cytosolic content of the pS2 protein in breast cancer]
| Autor: | F, Tamargo, F, Vizoso, M L, Lamelas, A, Rodil, P, Vérez, P, Raigoso, M, Mulero, J, Vázquez, C, Roiz, M T, Allende |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Neoplasms Hormone-Dependent Tumor Suppressor Proteins Carcinoma Ductal Breast Radioimmunoassay Proteins Breast Neoplasms Cell Differentiation Estrogens Prognosis Neoplasm Proteins Cytosol Receptors Estrogen Lymphatic Metastasis Biomarkers Tumor Humans Female Trefoil Factor-1 Menopause Receptors Progesterone Progesterone |
| Zdroj: | Revista espanola de medicina nuclear. 21(1) |
| ISSN: | 0212-6982 |
| Popis: | To analyze pS2 cytosolic levels in breast carcinomas and their correlation with different clinical characteristics of the patients and their tumours.Cytosolic pS2 levels were measured by radioimmunometric assay in tumours from 168 breast cancer patients.The pS2 values ranged from 0 to 251 ng/mg protein (mean SD: 21.8 38.1; median: 7.9 ng/mg protein). These protein levels were significantly (p0.05) higher in premenopausal patients (27.6 45.2) than in postmenopausal patients (19.5 33.8). Intratumour pS2 levels were also significantly (p0.05) correlated with histologic grade of the tumours, and were higher in well diferentiated tumours (grade I: 28.8 42.8) than in moderately differentiated tumours (grade II: 19.7 35.6) and than in poorly differentiated tumours (grade III: 18.9 37.3). Similarly, significant differences in pS2 content were found between positive estrogen receptor (ER) tumours and ER-negative tumours (29.1 46.5 vs 11.3 15.9, respectively; p0.0001), as well as between positive progesterone receptor (PR) tumours and PR-negative tumours (29.1 49.8 vs 15.3 21.5, respectively; p0.05).The results suggest that pS2 may be a useful prognostic marker in breast cancer, and may also be useful to identify patients who are likely to benefit from hormone therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|